Your session is about to expire
← Back to Search
GLP-1 Receptor Agonist
GLP-1 for Type 1 Diabetes
Phase < 1
Recruiting
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
40 (20 males, 20 females) individuals with type 1 diabetes aged 18-50 yr.
No clinically diagnosed diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
Study Summary
This trial will test whether GLP-1 can help protect against the harmful effects of hypoglycemia in people with T1DM.
Who is the study for?
This trial is for adults aged 18-50 with Type 1 Diabetes, a BMI under 40kg/m2, and HbA1c levels below 11.0%. Participants should not have diabetic complications like retinopathy or neuropathy. They must not be pregnant, have significant heart issues, severe liver or kidney problems, anemia, or be on certain medications like beta blockers or anticoagulants.Check my eligibility
What is being tested?
The study tests if Glucagon-like peptide-1 (GLP-1) can protect blood vessel function and reduce the risk of blood clots after low blood sugar events in people with Type 1 Diabetes. Some participants will receive GLP-1 while others will get a placebo to compare effects.See study design
What are the potential side effects?
Possible side effects of GLP-1 may include digestive issues such as nausea and vomiting, potential allergic reactions, headache, dizziness and might affect blood sugar levels which need careful monitoring.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 50 years old with type 1 diabetes.
Select...
I do not have complications from diabetes like eye or nerve problems.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in the level of catecholamines in plasma
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: GLP-1Experimental Treatment1 Intervention
The participants will be randomized to Glucagon-like peptide-1 infusion.
Group II: Placebo 1Placebo Group1 Intervention
The participants will be randomized to placebo infusion.
Group III: Placebo 2Placebo Group1 Intervention
The participants will be randomized to placebo infusion.
Find a Location
Who is running the clinical trial?
University of Maryland, BaltimoreLead Sponsor
688 Previous Clinical Trials
374,616 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am unable or unwilling to follow the required contraception guidelines.I have recently had a stroke or brain injury.Your liver function tests show levels of SGOT and SGPT that are more than twice the normal range.I do not have uncontrolled high blood pressure or a history of severe heart or brain blood vessel problems.I am not taking medications like beta blockers, sedatives, or antidepressants.I do not have serious heart problems.Your alkaline phosphatase levels are higher than 150 units per liter.Your liver enzyme levels are more than twice the normal range.Your body mass index is less than 40.Your hematocrit level is lower than 32.Your creatinine levels are higher than 1.6 mg/dl.I have had a fever over 38.0 C.Your HbA1c level is below 11.0%.I am unable to understand and give consent for my own treatment.I do not have liver failure or jaundice.You have important abnormal results from screening tests and physical exams.I do not have complications from diabetes like eye or nerve problems.I am between 18 and 50 years old with type 1 diabetes.Your total bilirubin level is higher than 2 mg/dl.Your white blood cell count is below 3 thousand per microliter or above 14 thousand per microliter.I have pneumonia.I am on blood thinners, have anemia, or a bleeding disorder.
Research Study Groups:
This trial has the following groups:- Group 1: GLP-1
- Group 2: Placebo 1
- Group 3: Placebo 2
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there an opportunity for me to be involved with this medical experiment?
"To be considerered for this trial, applicants must have type 1 diabetes mellitus and fall within the specified age range (18 to 50). Currently, there is space available for 40 participants."
Answered by AI
Is recruitment for this experiment ongoing?
"According to information on clinicaltrials.gov, this medical study is actively searching for participants. The trial was first posted June 24th 2020 and most recently updated April 8th 2022."
Answered by AI
Is there an age restriction for participants in this trial?
"This clinical trial necessitates that participants are below 50 years of age and have reached the legal age of consent."
Answered by AI
How many volunteers is this trial recruiting?
"Correct. Clinicaltrials.gov provides evidence that this medical trial is recruiting, with the initial post having been made on June 24th 2020 and updated as recently as April 8th 2022. 40 people must be recruited from a single site in order to move forward with the study."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger